Celldex Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview

Celldex Therapeutics

02/08/2024 14:15

* Celldex Therapeutics Inc  CLDX.OQ   CLDX.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 6
(estimated) for the period ending June 30 2024
    * The Hampton New Jersey-based  company is expected to
report a
206.1% increase in revenue to $820.43 thousand from $268
thousand a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Celldex Therapeutics Inc
is
for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $68.00​, above​ its last closing price
of $37.55. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.70       -0.69      -0.56     Beat    19.3
 Dec. 31 2024  -0.76       -0.74      -0.83     Missed  -11.6
 Sep. 30 2023  -0.68       -0.68      -0.81     Missed  -19.4​
 Jun. 30 2023  -0.67       -0.67      -0.65     Beat    2.5
 ​​Mar.        -0.63       -0.63      -0.62     Beat    1.9
 31 2023                                                
 Dec. 31 2022  -0.59       -0.59      -0.56     Beat    5.1​
 Sep. 30 2022  -0.57       -0.58      -0.57     Beat    1.2
 Jun. 30 2022  -0.51       -0.51      -0.59     Missed  -15.7
 This summary was machine generated August 2 at 13:15 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)